Areteia Announces Appointment of Daniel Becker To Board of Directors
Areteia Therapeutics Announces Additional $75MM in Series A Financing
Areteia to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Areteia Therapeutics Announces Publication of Phase II Data of Oral Dexpramipexole in Eosinophilic Asthma
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Elyse Stock, M.D. to the Areteia Board of Directors, effective April 17, 2023. Dr. Stock will serve as a member of the compensation, nominating and corporate governance committee of the board.
Areteia Therapeutics has dosed the first participants in the EXHALE-2 and EXHALE-4 clinical trials of oral dexpramipexole in severe eosinophilic asthma patients.
Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma